68Ga-Fapi PET/CT for Imaging of Fibrosis in IgG4-related Disease: Comparison to 18F-FDG PET/CT
Yaping Luo,Qingqing Pan,Zhang Wen,Fang Li
2020-01-01
Journal of Nuclear Medicine
Abstract:544 Objectives: IgG4-related disease (IgG4-RD) is characterized by lymphoplasmacytic infiltration enriched in IgG4-positive plasma cells and variable degrees of fibrosis with a characteristic storiform pattern[1, 2]. As fibrosis is one of the key factors to understand the pathogenesis of IgG4-RD, we tried to investigate if 68Ga-FAPI, a recently introduced PET agent targeting fibroblast activation protein[3-5] had some role in management of IgG4-RD. Methods: The study was approved by the institutional review board of our hospital and registered at Clinicaltrial.gov (NCT 04125511). A total of 23 patients diagnosed with IgG4-RD (18 male, 5 female; age, 52.0 ± 13.9 yr, range 17-64 yr) in the Department of Rheumatology of the Peking Union Medical College Hospital were consecutively recruited from Feb 2019 to November 2019. Written informed consent was obtained from each patient. All recruited patients fulfilled the 2019 ACR/EULAR consensus criteria of IgG4-RD[6]. Eighteen patients had newly diagnosed IgG4-RD that was treatment-naive, and 5 patients had a previous history of IgG4-RD and had been treated with prednisone. The median level of serum IgG4 was 14600 (range, 355-73400) mg/L (normal limits 80-1400 mg/L). Fourteen patients (60.9%) underwent biopsy for diagnosis of IgG4-RD (biopsy site: pancreas [n=6], salivary gland [n=4], lacrimal gland [n=2], lymph node [n=2], gall bladder [n=1], lung [n=1]). After enrollment, patients were referred for 18F-FDG and 68Ga-FAPI PET/CT for evaluation of the disease, which were carried out within 1 week. The imaging characteristics were analyzed afterwards. Results: In the recruited patients, IgG4-RD most commonly involved the pancreas (18/23, 78.3%), salivary gland (18/23, 78.3% [submandibular gland, 18/23, 78.3%; parotid, 7/23, 30.4%; sublingual gland, 7/23, 30.4%]), lymph nodes (16/23, 69.6%), and lacrimal gland (14/23, 60.9%, extraocular muscle was also involved in one patient) according to 68Ga-FAPI and 18F-FDG PET/CT. Other involved organs included the lung (8/23, 34.8%), pleura (5/23, 21.7%), bile duct and liver (6/23, 26.1%), retroperitoneal fibrosis/periaortitis (6/23, 26.1%), kidney (4/23, 17.4%), prostate (9/23, 39.1%), seminal vesicle (2/23, 8.7%), nasal cavity (3/23, 13.0%), pituitary stalk (1/23, 4.3%), stomach (1/23, 4.3%), and peritoneum (1/23, 4.3%). In a total of 127 organ involvements in the 23 patients, 68Ga-FAPI PET/CT additionally detected 18/127 (14.2%) organ involvements in 12/23 (52.2%) patients compared with 18F-FDG PET/CT (FAPI+/FDG-), including the disease in the pancreas (7/18), lacrimal gland (4/14), sublingual gland (2/7), submandibular gland (1/18), bile duct and liver (2/6), nasal cavity (1/3), and stomach (1/1). However, all of the lymph node involvements that were FDG-avid were missed by 68Ga-FAPI PET/CT, which may be attributed to the fact that lymph node involvement in IgG4-RD usually lacks the characteristic storiform fibrosis[1, 2]. When comparing the uptake in organ involvements and the extension of the disease detected in PET/CT, 68Ga-FAPI PET/CT showed visually higher uptake or detected more extensive disease than 18F-FDG PET/CT in pancreas, bile duct/liver, salivary gland and lacrimal gland in more than 40% of the recruited patients. The detection rate and visual comparison of 68Ga-FAPI and 18F-FDG PET/CT in IgG4-RD involvements is shown in Table 1 and Figure 1 (examples of dual-tracer PET/CT in IgG4-RD shown in figure 2). Conclusions: 68Ga-FAPI might be a promising imaging agent for the assessment of IgG4-RD.